Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Icahn predicts 40% premium in Visx sell off

This article was originally published in Clinica

Executive Summary

Carl Icahn, a US financier who for some months has been aggressively attempting to take control of US laser eye surgery company Visx, has raised the stakes by claiming that he will be able to sell the company to an unnamed bidder for $32 a share if he gained control. That would represent a premium of more than 40% on the company's present share price of just over $19.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts